Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#70 What Is the Risk of VTE with Various Hormonal Contraceptives?


CLINICAL QUESTION
QUESTION CLINIQUE
How does the risk of venous thromboembolism (VTE) risk compare between hormonal contraceptives?


BOTTOM LINE
RÉSULTAT FINAL
Due to limits in the evidence, there is uncertainty whether the risks of VTE vary with different hormonal contraceptives. If they do, the increased risk appears to be about one extra VTE a year per 1,250 women.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
There are no long-term randomized controlled trials, which leaves cohort and case-control studies as best evidence. 
  • Studies that found different VTE risk between hormonal contraceptives: 
    • Combined oral contraceptives (COCs): 3rd generation progestins (desogestrel, drospirenone, gestodene, norgestimate, cyproterone) increase VTE risk (about 1.5-2x) over 1st or 2nd generation progestins (levonorgestrel or norethisterone).1-4 
    • Transdermal estrogen and vaginal ring increase VTE risk (about 2x) over combined oral contraceptive (COC) with levonorgestrel.5 
    • Levonorgestrel intra-uterine device (IUD) or progestin-only pills have same VTE risk as non-users.5 
    • Lower-dose estrogen reduces VTE risk.2 
  • Other studies found no increased VTE risk with drospirenone,6 transdermal patch,1 or vaginal ring.7 
  • If these differences are real, the absolute VTE risk per 10,000 woman-years (or 1,000 women over 10 years) may be approximately: 
    • 2-3 for non-users or women using progestin-only pills or progestin IUD.1 
    • 7-9 for use of COC with levonorgestrel or norethisterone.1-3 
    • 10-15 for use of COC with 3rd generation progestin, transdermal patch, or vaginal ring.1,3,5 
    • 29 for pregnancy (for comparison).1 
Context:  
  • Society of Obstetricians and Gynecologists of Canada (SOGC)8 have previously stated evidence regarding risk of VTE with different progestins is inconclusive due to mixed results and high risk of bias. 
  • To keep the risk differences in perspective, 1,000-1,250 women would need to switch from higher- to lower-risk of COC to prevent one VTE per year.1,3 
  • Even the largest studies using confirmed VTE3-5 were retrospective and had potential confounding, leaving uncertainty if increased risk is real. 
  • Other factors influencing VTE risk are age (45-49 about 6x risk age 15-19),3,9 obesity (BMI ≥35 about 4x risk of BMI 20-25),3,10 and smoking (about 2x risk).3,10 
updated by ricky July 28, 2016


Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Sudha Koppula MD MCISc CCFP

1. Martinez F, Ramirez I, Perez-Campos E, et al. Eur J Contracept Reprod Health Care. 2012; 17:7-29.

2. de Bastos M, Stegeman BH, Rosendaal FR, et al. Cochrane Database Syst Rev. 2014; 3:CD010813.

3. Vinogradova Y, Coupland C, Hippisley-Cox J. BMJ. 2015; 350:h2135.

4. Weill A, Dalichampt M, Raguideau F, et al. BMJ. 2016; 353:i2002.

5. Lidegaard O, Nielsen LH, Skovlund CW, et al. BMJ. 2012; 344:e2990.

6. Dinger JC, Heinemann LA, Kühl-Habich D. Contraception. 2007; 75:344-54.

7. Dinger J, Mohner S, Heinemann K. Obstet Gynecol. 2013; 122:800-8.

8. Reid R, Leyland N, Wolfman W, et al. Int J Gynaecol Obstet. 2011; 112:252-6.

9. Lidegaard O, Nielsen LH, Skovlund CW, et al. BMJ. 2011; 343:d6423.

10. Lawrenson R, Farmer R. Contraception. 2000; 62:21S-28S.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 28/07/2016

By: Ricky D. Turgeon BSc(Pharm) ACPR PharmD

Comments:

Evidence Updated: New evidence; Bottom Line: Modified, no major change.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks